Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-04
2011-11-22
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S518000
Reexamination Certificate
active
08063095
ABSTRACT:
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I:or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
REFERENCES:
patent: 5750646 (1998-05-01), Coy et al.
patent: 6110691 (2000-08-01), Wang et al.
patent: 6423689 (2002-07-01), Booth et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 6992063 (2006-01-01), Shi
patent: 7041784 (2006-05-01), Wang et al.
patent: 7094758 (2006-08-01), Wang et al.
patent: 7229617 (2007-06-01), Nasoff et al.
patent: 7419975 (2008-09-01), Palermo et al.
patent: 7547724 (2009-06-01), Laurent et al.
patent: 7579320 (2009-08-01), Boudreault et al.
patent: 7589118 (2009-09-01), Laurent et al.
patent: 7645741 (2010-01-01), Boudreault et al.
patent: 7718600 (2010-05-01), McLendon et al.
patent: 7772177 (2010-08-01), Jarvis et al.
patent: 2004/0180828 (2004-09-01), Shi et al.
patent: 2005/0197403 (2005-09-01), Harran et al.
patent: 2006/0014700 (2006-01-01), Cohen et al.
patent: 2006/0025347 (2006-02-01), Condon et al.
patent: 2006/0194741 (2006-08-01), Condon et al.
patent: 2006/0211627 (2006-09-01), Reed et al.
patent: 2006/0258581 (2006-11-01), Reed et al.
patent: 2007/0032437 (2007-02-01), Shi et al.
patent: 2007/0042428 (2007-02-01), Springs et al.
patent: 2007/0093428 (2007-04-01), Laurent
patent: 2007/0093429 (2007-04-01), Laurent et al.
patent: 2007/0219140 (2007-09-01), Laurent et al.
patent: 2008/0069812 (2008-03-01), Boudreault et al.
patent: 2008/0089896 (2008-04-01), Wang et al.
patent: 2008/0207525 (2008-08-01), Boudreault et al.
patent: 2 491 041 (2004-01-01), None
patent: 2 582 734 (2005-09-01), None
patent: 2 560 162 (2005-10-01), None
patent: 2 574 040 (2006-02-01), None
patent: 61183297 (1986-08-01), None
patent: 04208299 (1992-07-01), None
patent: WO 92/02545 (1992-02-01), None
patent: WO 92/12168 (1992-07-01), None
patent: WO 00/01726 (2000-01-01), None
patent: WO 02/26775 (2002-04-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 03/086470 (2003-10-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2005/069888 (2005-08-01), None
patent: WO 2005/074989 (2005-08-01), None
patent: WO 2005/084317 (2005-09-01), None
patent: WO 2005/094818 (2005-10-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/010118 (2006-01-01), None
patent: WO 2006/014361 (2006-02-01), None
patent: WO 2006/017295 (2006-02-01), None
patent: WO 2006/020060 (2006-02-01), None
patent: WO 2006/069063 (2006-06-01), None
patent: WO 2006/113376 (2006-10-01), None
patent: WO 2006/122408 (2006-11-01), None
patent: WO 2006/128455 (2006-12-01), None
patent: WO 2006/133147 (2006-12-01), None
patent: WO 2007/048224 (2007-05-01), None
patent: WO 2007/075525 (2007-07-01), None
patent: WO 2007/101347 (2007-09-01), None
patent: WO 2007/104162 (2007-09-01), None
patent: WO 2007/106192 (2007-09-01), None
patent: WO 2007/130626 (2007-11-01), None
patent: WO 2007/131366 (2007-11-01), None
patent: WO 2007/136921 (2007-11-01), None
patent: WO 2008/014229 (2008-01-01), None
patent: WO 2008/014236 (2008-01-01), None
patent: WO 2008/014238 (2008-01-01), None
patent: WO 2008/014240 (2008-01-01), None
patent: WO 2008/014252 (2008-01-01), None
patent: WO 2008/014263 (2008-01-01), None
patent: WO 2008/016893 (2008-02-01), None
patent: WO 2008/045905 (2008-04-01), None
patent: WO 2008/057172 (2008-05-01), None
patent: WO 2008/067280 (2008-06-01), None
patent: WO 2008/073306 (2008-06-01), None
patent: WO 2008/079735 (2008-07-01), None
patent: WO 2008/085610 (2008-07-01), None
patent: WO 2008/128121 (2008-10-01), None
patent: WO 2008/128171 (2008-10-01), None
patent: WO 2008/134679 (2008-11-01), None
patent: WO 2008/144925 (2008-12-01), None
patent: WO 2009/060292 (2009-05-01), None
patent: WO 2009/136290 (2009-11-01), None
patent: WO 2009/140447 (2009-11-01), None
patent: WO 2009/152824 (2009-12-01), None
patent: WO 2009/155709 (2009-12-01), None
patent: WO 2010/015090 (2010-02-01), None
patent: WO 2010/017035 (2010-02-01), None
patent: WO 2010/031171 (2010-03-01), None
patent: WO 2010/033531 (2010-03-01), None
Extended European Search Report, European Application No. EP 06 79 0872, mailed Mar. 30, 2010.
Arnt et al.,J. Biol. Chem., “Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in Situ,” 277(46): 44236-44243 (2002).
Bertrand et al.,Mol. Cell, “cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination,” 30: 689-700 (2008).
Bucher et al.,Helv. Chim. Acta., 78(4):935-46 (1995).
Chai et al.,Nature, “Structural and biochemical basis of apoptotic activation by Smac/DIABLO,” 406: 855-62 (2000).
Chauhan et al.,Blood, “Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM),” 109(3): 1220-7 (2007).
Eckelman et al.,Cell Death Differ., “The mechanism of peptide-binding specificity of IAP BIR domains,” 15(5): 920-8 (2008).
Elmore et al.,Annual Rep. Med. Chem., “Inhibitors of Anti-apoptotic Proteins for Cancer Therapy,” 40: 245-62 (2006).
Franklin et al.,Biochemistry, “Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP),” 42: 8223-31 (2003).
Fulda et al.,Nature Medicine, “Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo,” 8: 808-15 (2002).
Gao et al.,J. Biol. Chem., “A dimeric Smac/Diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo,” 282(42): 30718-27 (2007).
Glover et al.,Anal. Biochem., “A High-Throughput screen for identification,” 320: 157-169 (2003).
Haining et al.,Proc. Natl. Acad. Sci. USA, “The proapoptotic function ofDrosophilaHID is conserved in mammalian cells,” 96(9): 4936-41 (1999).
IAP from GenBank Accession No. Q13490, pp. 1-6. Accessed Jul. 1, 2008.
Interferon Gamma from GenBank Accession No. NP—776511, pp. 1-3. Accessed Jul. 1, 2008.
Kipp et al.,Biochemistry, “Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners,” 41: 7344-9 (2002).
Liu et al.,Nature, “Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain,” 408: 1004-8 (2000).
Marik et al.,J. Peptide. Res., “Synthesis and effect of shortened oostatic decapeptide (TMOF) analogs with isosteric structures on reproduction ofNeobellieria bullata,”57(5): 401-8 (2001).
McCarthy et al.,J. Biol. Chem., “Apoptosis induced byDrosophilareaper and grim in a human system. Attenuation by inhibitor of apoptosis proteins (cIAPs),” 273(37): 24009-15 (1998).
Nikolovska-Coleska et al.,Anal. Biochem., “Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization,” 332: 261-273 (2004).
Nikolovska-Coleska et al.,Anal. Biochem., “Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains,” 374(1): 87-98 (2008).
Petersen et al.,Cancer Cell, “Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis,” 12(5): 445-56 (2007).
Srinivasula et al.,J. Biol. Chem., “Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway,” 275(46): 36152-7 (2000).
Sun et al.,J. Am. Chem. Soc., “Structure-Based Design of Potent, Conformationally Constrained Smac Mimetics,” 126(51): 16686-87 (2004).
Sun et al.,J. Med. Chem., “Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of casp
Boudreault Alain
Bureau Patrick
Hewitt Kim
Jaquith James
Jarvis Scott
Kosack Joseph
Leydig , Voit & Mayer, Ltd.
Pharmascience Inc.
LandOfFree
IAP BIR domain binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IAP BIR domain binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IAP BIR domain binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301488